
|Articles|September 1, 2003
Fungoides Foiler
San Francisco - Cytokine therapies that enhance the T-helper 1 (TH1) response may be the key to effective treatment of mycosis fungoides, according to David P. Fivenson, M.D. The treatments, still in the investigative stage, have potential advantages over existing treatments because their selectivity of action also reduces the risk of nonselectivity-related toxicity, he said, noting that mycosis fungoides is now typically termed cutaneous T-cell lymphoma.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















